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Background: The size and increasing burden of disease due to mental disorders in Europe 
poses substantial challenges to its population and to the health policy of the European Union. 
This warrants a specific research agenda concerning clinical mental health research as one of the 
cornerstones of sustainable mental health research and health policy in Europe. The aim of this 
research was to identify the top priorities needed to address the main challenges in clinical 
research for mental disorders.
Methods: The research was conducted as an expert survey and expert panel discussion during 
a scientific workshop.
Results: Eighty-nine experts in clinical research and representing most European countries 
participated in this survey. Identified top priorities were the need for new intervention studies, 
understanding the diagnostic and therapeutic implications of mechanisms of disease, and research 
in the field of somatic-psychiatric comorbidity. The “subjectivity gap” between basic neuro-
science research and clinical reality for patients with mental disorders is considered the main 
challenge in psychiatric research, suggesting that a shift in research paradigms is required.
Conclusion: Innovations in clinical mental health research should bridge the gap between 
mechanisms underlying novel therapeutic interventions and the patient experience of mental 
disorder and, if present, somatic comorbidity. Clinical mental health research is relatively 
underfunded and should receive specific attention in Horizon 2020 funding programs.
Keywords: clinical research, mental health, randomized clinical trials, Horizon 2020, expert 
survey, challenge, research agenda, Europe
Introduction
Given the sizeable burden and costs associated with mental disorders,1–6 the European 
Union has called for a systematic approach toward research in this area. The “ROAdmap 
for MEntal health Research and well-being in Europe” (ROAMER) project, funded by 
the European Commission’s Seventh Framework Programme, was given the task of 
developing a mental health research roadmap based on expert consultation covering 
various domains in the field (ie, psychological research, biomedical research, research 
funding, infrastructures, and capacity building, research on social and economic aspects, 
and research on well-being and public health), as well as on the views of other stakehold-
ers, such as service users, carers, professionals, and policy and funding institutions.7 
Several work packages within ROAMER have already published about their priorities, 
such as public health research needs for improvement of mental health in Europe,8 the 
core aspects of biomedical and psychological mental health research and their possible 
role in diagnosis and treatment of mental disorders,9–13 as well as the views of national 
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associations/organizations of psychiatrists, other mental 
health professionals, users and/or carers, and psychiatric 
trainees in the 27 countries of the European Union about the 
priorities for mental health research in Europe.14 Subsequently, 
within ROAMER, clinical mental health research was recog-
nized as an area of particular interest, given the growing gap 
between the enormous output of neuroscience research and 
the actual impact of research on clinical treatment for patients 
with mental disorders.15 Clinical mental health research aims 
to translate such research findings by applied research aimed 
at improving the health of individuals with mental disorders 
and thus is required to bridge this gap. Current treatment of 
mental disorders usually requires complex and multilevel 
interventions targeting morbidity and mortality reduction, ie, 
prevention of suicide,16,17 detection and treatment of mental 
disorders by consultation models,18,19 and collaborative care 
models integrating primary care and specialty mental health 
care,20 and by integrating psychopharmacological, medical, 
psychotherapeutic, psychological, system, and societal inter-
ventions aimed at return to functioning and work with systems 
of care delivery. Clinical mental health research thus requires 
a multidisciplinary approach and a translational perspective. 
A research agenda exploring gaps and challenges, as well as 
the actions needed to address these challenges, is warranted. 
Therefore, the Clinical Research Task Force was established 
within ROAMER in order to perform such a survey, address-
ing these issues among experts in the field of clinical mental 
health research. The findings of the first round of this survey 
are presented in this paper.
Materials and methods
Procedure
The survey aimed to gain an insight into the challenges, 
gaps, and advances needed in clinical research in the field 
of mental disorders. It was performed among experts in this 
field and consisted of two rounds. The first round, performed 
from February to April 2013, aimed at setting priorities for 
mental health research, and the second round, performed 
from July to September 2013, focused on consensus among 
the experts. It was a web-based survey using Webropol 2.0 
online survey and analysis software.21 Experts were asked 
to follow an individualized survey link to read the informed 
consent statement and to participate. The link was unique 
to each putative participant, and could not be forwarded to 
anyone else. Nonrespondents received reminder emails every 
third day and were approached by ambassadors and personal 
contacts from the ROAMER Clinical Research Taskforce in 
each country. The results of the first round were discussed 
during a scientific workshop in Amsterdam, March 18, 2013, 
in which the Clinical Research Task Force consulted experts 
in the field of clinical research on mental disorders. The cur-
rent paper reports the results of the first round of the expert 
study as well as the results of the scientific workshop in 
Amsterdam. Analysis of the first round of the survey resulted 
in selection of main challenges as well as in prioritizing of 
the advances required to address these challenges, which 
are presented in the Results section. Discussions during the 
scientific workshop provided us with a broader perspective to 
interpret the findings of the first round of the survey, described 
in the Discussion section of this paper.
selection of participants
In total, 313 experts in clinical mental health research were 
invited to participate, beginning on February 21, 2013 
through April 8, 2013. They were selected by the members 
of the ROAMER Clinical Research Task Force according to 
one of the following criteria: 
•	 minimum h-index of 10 in Web of Science,22 or more 
than 50 publications in the field in Web of Knowledge
•	 experts who had been consulted in the Grand Challenges 
in Global Mental Health survey,23 who were scrutinized in 
duplicate (RK, CMFC) in order to identify all European 
experts involved in clinical research
•	 principal investigators carrying out clinical research in 
Europe were selected (RK, SK) from several databases 
for clinical research, such as the http://www.trialregister.
nl/trialreg/index.asp trial register and the Web of Knowl-
edge; the search terms used were in concordance with 
those used for other ROAMER activities and are shown 
in the Supplementary material
•	 from the list of experts already consulted by ROAMER 
in lieu of other surveys, the experts who published on 
clinical research topics in the Web of Knowledge in the 
last 5 years were selected (CMFC)
•	 ROAMER Clinical Research Task Force members were 
asked to list the most important experts from their own 
network using the same criteria
•	 in order to involve experts from as many European coun-
tries as possible, and thus attain sufficient representation 
in the survey with experts from all over Europe, members 
of ROAMER from countries with low representation, 
taking into account criteria 1 to 5, were asked to suggest 
experts meeting these criteria (DL, KW)
•	 ROAMER work package leaders involved in clinical 
research as well as the coordinator of ROAMER were 
also invited to participate.
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survey questions
The first round of the survey consisted of three sections: first, 
there was an open-ended section with questions on challenges 
and advances needed, followed by a section listing a priori 
challenges that the experts were asked to rate, and finally, an 
open section in which experts could propose advances that 
were required in order to address the challenges.
section i: open question on challenges  
and advances
The expert survey started with a definition of a challenge in 
clinical research: “In line with previous initiatives, a chal-
lenge in clinical research is defined as “a specific barrier that, 
if removed, would help to solve an important health problem. 
If successfully implemented, the intervention(s) could lead to 
a high likelihood of feasibility for scaling up and impact.”11 
Subsequently, the experts were asked an open-ended ques-
tion on perceived challenges in the field of clinical mental 
health research, as follows: “Please list your core challenge 
in Clinical Research on Mental Health and Well-Being in 
Europe – irrespective of any specific disease area or age 
group.” The experts could list up to five such challenges.
section ii: a priori gaps and policies
In addition to the open-ended section on challenges, the 
first-round questionnaire also included 23 a priori general 
gaps, nine a priori methodological gaps, and ten a priori 
possible policies required to close those gaps identified by 
the Clinical Research Task Force and the ROAMER board, 
based on preliminary expert consultation (SK, CMFC). 
Experts participating in the survey were asked to rate these 
gaps using close-ended questions as follows. For the general 
gaps, the response could be chosen from: 1 (I do not see this 
as a gap), 2 (no priority), 3 (modest priority), and 4 (high 
priority). For the methodological gaps, the response could 
be either 1 (I do not see this as a gap) or 2 (I do see this as 
a gap). For the ten possible policies required to close gaps 
and advance challenges in clinical research, the possible 
responses were: 1 (I do not agree), 2 (I half-half), and 3 
(I fully agree). Experts could not skip through or go back 
through the survey, so contamination of section 1 with 
items of section 2 could not occur and the rate of missing 
data was limited.
section iii: open questions on advances and their 
prioritization identified by experts
The last section contained open-ended questions prompting 
the experts to choose the three highest rated challenges from 
the first two sections, and to suggest advances to address 
these challenges. Input was provided by a member of the 
Scientific Advisory Board on how to conduct surveys and 
how to interpret their results.24
analysis
The first open-ended question section resulted in a range 
of items (challenges) that survey participants evaluated as 
suitable for prioritization in clinical research. Items were 
categorized into twelve categories (themes) in duplicate and 
independently by two post-doctoral researchers (IE, SK). 
Duplicates and redundancies were removed (IE, SK). The 
Webropol survey program calculated means in the event of 
more than two-item scales, or percentages in the event of two-
item scales, and provided the expert ratings on the respective 
a priori challenges and policy advances. Qualitative analysis 
of the data from the three sections of the questionnaire was 
done to identify the highest priority general challenges 
and advances for clinical research, and the highest priority 
methodological challenges, rated as such by the experts. 
These were subsequently discussed with the experts during 
the invitational conference.
Results
Participants
A total of 313 experts were invited for participation. Of these, 
105 (34%) were identified as having accessed the system; 
an unknown number of experts did not receive the emails 
containing an invitation for and access to the survey. Of the 
105 respondents identified to have accessed the website for 
the survey, 89 (response rate 85%; 28.4% of all those invited; 
79% male respondents; mostly aged .50 years) from a vari-
ety of European countries participated in the first round of 
the survey. The respondents represented almost all European 
countries, with an overrepresentation of the Netherlands and 
the UK, which are the most productive countries in terms of 
clinical mental health research, particularly in randomized 
controlled trials (Figure 1).
Respondents were mostly psychiatrists, psychologists, 
general physicians, and some occupational physicians 
who represented different areas in the field of clinical 
research. The best represented areas were clinical trials 
(71%), epidemiology and public health research (41%), 
health services research (34%), and basic research (30%). 
Experts represented different professional grades, dis-
ciplines, and institutions, with an overrepresentation of 
professors (74%) working at universities or in university 
hospitals (86%).
Neuropsychiatric Disease and Treatment 2014:10
Table 1 general challenges for clinical mental health research
Challenges Rating
1.  Development of new treatment interventions  
(pharmacological, brain-related [eg, deep brain  
stimulation], psychotherapeutic, systemic, psychosocial,  
e-Health/m-Health approaches and virtual reality/gamification  
or a combination of these, for mental disorders
3.6
2. exploring the mechanisms of diseases 3.5
3. evaluation of treatment effects 3.4
4. Proof of concept clinical trials for innovative treatments 3.3
5.  role of comorbidity between mental disorders and  
somatic conditions for diagnoses, treatment decisions,  
and treatment and patient-related outcomes
3.3
Notes: Number of respondents: 87. complete rating table experts first round: 
23 items. range 2.6–3.6.
Table 2 Methodological challenges for clinical mental health 
research
Challenges Rating
1. Design of psychotherapeutic intervention studies 73%
2. Design of patient preference studies 51%
3. Design of psychopharmacological intervention studies 46%
4. Use of placebos in clinical research 41%
5. Performing cohort studies in clinical populations 41%
Notes: Number of respondents: 84. complete methodological rating table experts 
first round: 11 items. Range 2%–73%.
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United Kingdom:
19%
Austria: 1%
Belgium: 1%
Finland: 2%
France: 3%
Germany: 9%
Greece: 1%
Hungary: 1%
Italy: 16%
Switzerland: 2%
Sweden: 2%
Spain: 7%
Romania: 1%
Poland: 1%
Norway: 1%
Netherlands: 31%
Figure 1 european countries represented by the sample of respondents.
challenges
Challenges identified regarding the open-ended questions 
in section I were reduced to 12 categories, and qualitative 
analysis showed substantial correspondence in challenges 
suggested by the experts in section I and the a priori-defined 
gaps and challenges in section II. Ratings of the experts for 
the predefined challenges therefore could be used to prioritize 
the combined challenges in sections I and II. The priority 
rating of the general challenges ranged from 2.6 to 3.6 in the 
23 general items, and the total mean was 3.04. Items in the 
upper half above the mean rating of the priority ratings thus 
were items with a priority of 3.3 or more. These are shown 
in Table 1.
The priority rating of the methodological challenges 
ranged from 2% to 73% in the eleven items. The mean 
percentage was 37%. The five items in the upper half of the 
priority ratings thus were items with a priority of over 37%. 
These are shown in Table 2.
advances
According to the experts, the challenge with the highest 
priority was: “to increase research on new intervention 
approaches in order to gain more insight into their work-
ing mechanisms and to successfully develop effective new 
interventions.”
According to the experts, advances required to meet this 
challenge were: research on strategies in order to foster adher-
ence to treatments or interventions; exploration of mediators 
and moderators of outcome; assessment of differential treat-
ment effects, ie, if specific approaches are more effective 
for specific subgroups; development of e-Health/m-Health 
approaches and assessment of the level of human contact 
needed to motivate individuals toward sustained use of 
e-Health/m-Health treatments; and incorporation of patient 
perspectives in treatment.
The challenge rated as second in terms of priority was: 
“to conduct research in order to reach a wider understanding 
of different mechanisms (eg, psychological mechanisms, 
biological mechanisms, brain mechanisms, molecular mecha-
nisms and environmental interactions) that may underlie 
diseases.”
Neuropsychiatric Disease and Treatment 2014:10
Table 3 Top three policies needed to meet the gaps in clinical 
research in europe
1.  Funding for independent (multinational) clinical trials  
in horizon 2020
2.77
2.  National funding for independent clinical trials 2.68
3.   adoption of common outcome measures in line with  
the patients’ expectations
2.48
Notes: Number of respondents: 87. complete rating table experts first round: 
10 items. range 2.2–2.77.
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The challenge rated third in priority was: “to conduct 
research on different approaches to evaluate treatment 
effects.” According to the experts, advances required to meet 
this challenge were of a more methodological nature, includ-
ing standardization of psychotherapeutic treatment studies, 
equivalence trials, research on side effects of treatments, 
alternative and/or nonrandomized designs, and improved 
reliability and validity of outcome measures.
The challenge rated fourth in priority was: “to perform 
proof of concept clinical trials for innovative treatments.” 
Experts indicated that advances of an infrastructural and 
methodological nature were required to meet this challenge 
and establish (European) research networks to coordinate and 
facilitate clinical research, and to identify or develop standard 
definitions and guidelines to increase the understanding of 
the term “proof of concept”.
The experts were asked to indicate if specific patient 
groups, age groups, or disorders should be targeted, but in 
general there was no inclination toward a specific group, 
except the one defined in the fifth challenge. Experts 
identified the fifth challenge as the need for specific atten-
tion focused on comorbidity between somatic and mental 
 disorders. The advances suggested by the experts to address 
this challenge were to develop and increase research in order 
to better understand the mechanisms of comorbidity between 
mental disorders and somatic conditions, including diagnostic 
strategies and interventions that target such comorbidity.
Policies
Finally, the three most prioritized policies indicated by the 
experts are shown in Table 3. These were an overall need for 
funding of randomized clinical trials in the field of clinical 
mental health research, the importance of Horizon 2020 in 
this respect, and adaption of outcome measures for research 
according to patients’ expectations.
Discussion
study limitations
The main limitation of this study is that it was based on 
a survey that was sent to 313 experts, of whom only 89 
 collaborated. Because of limitations imposed by spam filters 
in operation at universities, we can only be sure that 105 
experts actually received the invitation for the survey, given 
that they accessed the system in order to indicate if they 
wished to collaborate, despite all efforts indicated earlier 
to contact experts in various ways. Thus, the response rate 
was 28%, which is within the range that can be expected for 
an email survey.
study strengths
There were also some strengths in this survey. First, generaliz-
ability of the results may be good because the participating 
experts were representative of the target sample of all experts 
in Europe. Of all respondents, 79% were male, most were 
aged older than 50 years, and most were professors from a 
variety of European universities and university hospitals. 
Nearly all EU-28 countries were represented. Second, the 
number of experts may be considered high compared with 
most other studies describing expert opinions on research. 
Third, we surveyed a priori challenges using open-ended 
questions, providing an opportunity to suggest new areas, 
while avoiding contamination with the a prior section. Finally, 
it is also noteworthy that all data extraction was performed 
independently in duplicate by two researchers, and the 
findings were discussed with experts during the scientific 
workshop.
Main findings: need for new interventions
Three of the five priority items highlighted an overwhelm-
ing need for development and scientific evaluation of new 
interventions for mental disorders in the field of clinical 
mental health research. This type of research may be referred 
to as “experimental medicine”, regardless of whether the 
mechanism under investigation is biological or  psychological. 
The interventions regarded to have potential range from 
biologically oriented interventions such as pharmacological 
interventions and deep brain stimulation to psychotherapeu-
tic, systemic, and social interventions. In addition, experts 
see potential for various kinds of treatments that use digital 
devices and/or information computer technology support, 
such as decision aids, m-Health, e-Health, and serious 
 gaming. e-Health and m-Health interventions are men-
tioned by the experts, with the specification that research 
is required to improve sustained use of these interventions 
by patients.12 An important issue is the risk of health care 
provider withdrawal and patient disengagement found in 
e-Health research25–30 and the need to examine e-Health and 
m-Health as tools to augment the process of face-to-face 
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care, rather than replace it.31 In Europe, industry is involved 
in information computer technology developments in the 
field of e-Health as well as m-Health, and this may provide 
Europe with opportunities to collaborate in this field in a 
precompetitive environment, combining efforts of companies 
and research in the context of Horizon 2020.
In the same vein, the creation of a precompetitive com-
bined research and industry environment may be needed in 
the context of Horizon 2020, given that many pharmaceuti-
cal companies have withdrawn from central nervous system 
research. Furthermore, new developments in neuroscience 
may open up opportunities for innovation in the future. This 
raises the question of to what degree governmental and 
independent funding will be able to develop new medica-
tions, possibly in collaboration with the pharmaceutical 
industry on an independent basis. A shift may be required 
in order to identify and test novel molecules in non-industry 
settings. Another challenge in the area of pharmacological 
interventions concerns the development of effective and 
safe algorithms for prescription of medication. For example, 
combinations of antipsychotic medications have rarely been 
tested, given that this type of research is rarely facilitated by 
the pharmaceutical industry, and is not routinely funded by 
the government either, whereas such research performed 
by independent clinical researchers may yield clinically 
relevant findings. For the same reason, head-to-head trials 
are also scarce, leaving many open questions on the relative 
benefit–risk of medicines for mental disorders.32
Another focus for research in this area concerns the study 
of possibly synergistic effects of combined psychopharma-
cological and psychotherapeutic interventions, given that the 
impact of pharmacological compounds is thought to be contin-
gent on experience-based alterations in the brain and mental 
functioning in many ways. A more synergistic approach may 
also help to inform about the moderators, mediators, or even 
mechanisms of behavior and behavioral change.10
Furthermore, the emphasis on European growth in 
 Horizon 2020 may support the indication by the experts of 
the importance of research into interventions aimed at return 
to work in sick-listed employees with a mental disorder; 
governmental organizations, trade unions, medical insurance 
companies, and social insurance companies may be relevant 
stakeholders in this effort.
Methodological advances needed  
for evaluation of treatment effects
A distinct need for innovation was identified, and in connec-
tion with this need, experts indicated that methodological 
advances are essential for intervention research. A need 
to develop methodology and design factors for proof-of-
concept trials evaluating novel treatments was identified, eg, 
relatively small trials exploring the possible effect of a new 
intervention by assessment of intermediary outcomes.
Methodological issues are considered a priority in relation 
to the need for new psychotherapeutic interventions as well. 
In psychotherapeutic intervention studies, blinding problems 
are an issue. Studies are required to explore possibilities to 
work with placebo conditions in psychotherapeutic trials, 
and to explore the neurobiological underpinnings of placebo 
effects in psychotherapeutic interventions.33 Also, equiva-
lence studies are needed as an alternative.  Standardization 
of psychotherapy in research is an important issue, particu-
larly in terms of replicability and internal integrity, as well 
as fidelity to treatment protocols. This problem, if properly 
addressed, could be translated to clinical practice by prag-
matic trials exploring treatment adherence of patients and 
therapists alike. Also, in randomized clinical trials and 
meta-analytic reviews in clinical mental health research, 
particular attention should be paid to diminishing potential 
bias and resultant loss of external validity.34 It should also be 
taken into account that methodological advances are needed 
to translate findings derived from often well prepared and 
well conducted clinical research into clinical practice, ie, by 
mixed-methods designs combining pragmatic randomized 
clinical trials with qualitative research evaluating conditions 
facilitating implementation of effective interventions.
Patient-oriented clinical intervention 
research
Experts in clinical research indicated a need for patient-
centered approaches. Among the advances suggested, the 
importance of tailoring treatments to specific patient profiles 
or diagnostic subgroups was mentioned as a high priority,35 
as well as the importance of patient-oriented clinical mental 
health research based on outcomes that are clinically relevant 
to patients. Outcomes of clinical mental health research can 
be specified at the level of the main symptom, global treat-
ment response, remission, or occurrence of relapse, but also 
at the level of quality of life and functioning, eg, in terms 
of work absenteeism in patients who are on sick leave. Also 
important as an outcome is societal participation other than 
work and the concept of personal recovery, reflecting the 
higher-order process of adaptation and self-management. 
Clinical mental health research should be sensitive to patient 
perspectives, and take into account patient preference in 
the design, experimental therapy, execution, and outcome 
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specification of randomized clinical trials, and address 
adherence of doctors and therapists as well as that of patients 
with treatment protocols as process or outcome measures. 
Research may also take the patient perspective into account 
with use of shared decision-making methods. Both pilot 
studies36 and randomized clinical trials using such treatment 
models and patient preference designs37 have been performed 
in Europe with promising results.38 Clinical research also 
encompasses the introduction of methodology to assess 
patient stratification in order to account for and target specific 
subgroups based on etiology and/or treatment sensitivity, 
such as in the application of risk profiles. Both efficacy and 
pragmatic randomized clinical trials are required in order to 
establish actual effectiveness in clinical practice, as well as 
cost-effectiveness.
concept and mechanisms of disease  
and somatic-psychiatric comorbidity
Among the five priorities identified by the experts, the first 
was the development and evaluation of new interventions, 
as described above. The other main emphasis, embedded in 
two of the five main challenges identified by the experts, was 
on what may be pertaining to current concepts of disease in 
psychiatry, particularly in terms of diagnosis and underlying 
mechanisms, as well as underlying mechanisms relevant for 
treatment, and the relationship between somatic and mental 
disorders.13 These were seen as areas for priority in clinical 
mental health research. There is wide consensus that diag-
nosis and classification in psychiatry, reflecting our current 
concepts of disease, is an area in need of improvement. 
Research in this area should result in the introduction of a 
system of functional diagnosis in psychiatry, ie, a system of 
diagnosis that is rich in information on the main functions that 
therapeutic interventions attempt to remediate.38 Insight into 
underlying mechanisms of etiology and particularly treatment 
are required to develop a system of functional diagnosis.24
Somatic-psychiatric comorbidity is frequent and associ-
ated with increased mortality.13 Management of these com-
bined conditions is intrinsically difficult due to diagnostic, 
treatment-related,39 and organizational difficulties,40 and there 
is an urgent need for the development and scientific evalu-
ation of new treatment modalities in this field, using both 
mental and somatic outcomes such as mortality and taking 
into account this diversity. From the perspective of the clini-
cal research experts, research should address diagnostic and 
treatment complexities in somatic-psychiatric comorbidity, 
with a focus on novel diagnostic and treatment algorithms 
designed to support medical decision-making. This need is 
closely linked to the other advances needed in terms of our 
understanding of the mechanisms of disease in clinical mental 
health research. This brings us to a main problem indicated 
by the experts.
subjectivity gap
Throughout the survey, experts indicated in different ways 
that there is little connection between much of the research 
in neuroscience, basic research, and imaging studies in 
psychiatry, and applied research in clinical practice, ie, 
both in clinical trials and in patients’ experience of the signs 
and symptoms of their mental disorders, and how these are 
approached, interpreted, and treated by professionals. Experts 
identified this as a major problem in mental health research. 
This problem may be referred to as the “subjectivity gap: 
the genotyping, imaging or other preclinical studies do not 
provide input regarding subjective experience. Similarly, 
they do not relate to diagnostic criteria, and the clinical 
practice of psychiatry”.
It has been noted that preclinical research to date has 
not yielded reliable diagnostic markers or markers for 
patient stratification in clinical practice.41 There is a need 
for clinical research addressing more precise and more 
patient-centered diagnostic assessments and patient-tai-
lored interventions, which may lead to so-called stratified 
medicine.35 There is also a potential for novel, reliable, 
and specific biomarkers as well as novel clinical mark-
ers that inform diagnosis of mental disorder. There is a 
need for intensive time-sampling process-related clinical 
assessments with potential to model symptom level or 
behavioral level change in a dynamic system of mental 
experience. Clinical process assessments may be combined 
with brain-related parameters for the purposes of diagnosis 
and prediction of treatment response. A combined focus on 
biological markers and the mental experience of patients 
may bridge the subjectivity gap and enrich research in 
mental health.
Some of the methodological advances recommended 
by the experts may be related to this underlying conceptual 
problem. The assumption that neurobiological processes 
represent causes of mental disorders cannot be validated by 
research;8 the only relationship that may exist may be a paral-
lel process of changes in social, mental, and neurobiological 
processes that can be induced by social, psychotherapeutic, 
and pharmacological interventions.8 Under that assumption, 
research is required that enables exploration of these perspec-
tives in a synergistic and nonhierarchical fashion. This would 
enable researchers to operationalize the working mechanism 
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of placebo as well as active conditions in psychotherapeutic 
interventions.16,42
If a link could be made between brain-oriented research 
and clinical mental health research, there should be no hier-
archy between neurobiological, pharmacological, psycho-
therapeutic, and social paradigms in patient-related clinical 
research. Such an effort would require multidisciplinary 
teams that connect basic researchers, clinical researchers, 
and conceptual philosophers, as well as patients with mental 
disorders, providing the researchers with insights in specific 
needs as part of a translational effort. Ultimately, this may 
yield novel concepts of mental disorder. If this challenge is 
taken seriously by Europe, funding and support of clinical 
research networks working together with basic scientists 
in a translational manner is required. Given the predictions 
regarding the health burden of mental disorders,22 imple-
mentation of such networks at the European level would be 
productive.
The European clinical research priorities presented in this 
paper add to the Grand Challenges in Global Mental Health 
Initiative, which identified global mental health research 
priorities in the next ten years.23 The initiative lists top global 
mental health challenges, ranked by disease-burden reduc-
tion, impact on equity, immediacy of impact, and feasibility. 
In parallel with the ROAMER findings, the Global Mental 
Health Initiative rank list is also topped by research topics 
related to improving treatments, eg, on integration of mental 
health service provision in primary health care and improv-
ing children’s access to evidence-based mental health care. 
Although methodological differences between the European 
and the global priority setting procedures preclude any firm 
comparative conclusions, it seems that European experts 
are more preoccupied with developing research methodol-
ogy, such as classification, standardization, and promotion 
of proof-of-concept studies. Also, anecdotal evidence sug-
gests that randomized clinical trials in the field of behavioral 
research are trailing behind in Europe in comparison with 
other countries, such as the USA. This type of clinical 
research, and the specific methodological attention required 
for innovation, eg, proof-of-concept trials, evaluation trials, 
pragmatic trials, and patient preference trials, tends to be 
overlooked and underfunded. Clinical mental health research 
in mental disorders should be brought more into line with 
other more medically oriented research. The difference 
between European and global priorities indicates that specific 
research needs exist in the European context and underlines 
the need for a specific European research agenda for mental 
health. Nevertheless, the fact that European Union mental 
health experts are putting together a Mental Health Horizon 
2020 agenda for enhancing the well-being and happiness of 
people in the European Union in particular and the world at 
large, by providing evidence-based, better quality interven-
tions for people suffering from mental disorders, may directly 
or indirectly provide other nations, including low-income, 
middle-income, and high-income countries, throughout the 
world with the opportunity to benefit from this planning 
and development framework. In the following second stage 
of the expert survey, we expect to focus further on how the 
experts expect to achieve the priorities and to analyze on 
which approaches consensus may be found.
The European Union research funding programs have 
been criticized for being too focused on biomedical research 
in the area of health, thus disregarding important translational 
research, such as implementation research, health systems 
and health policy research, and public health research.43,44 
Indeed, in 2011, only 4% of the €642 million cooperation 
program for health research in 2011 was allocated to these 
fields.45 Our results indicate that randomized clinical tri-
als in the field of mental disorders and translational and 
implementation research need a more visible position in the 
Horizon 2020 program than in previous European Union 
health research activities.
Conclusion
Innovations in clinical mental health research should bridge 
the gap between mechanisms underlying novel therapeutic 
interventions and patient experience of mental disorder 
and, if present, somatic comorbidity. Development of new 
interventions is needed, as well as studies evaluating these 
interventions, and pragmatic trials evaluating how to dis-
seminate and translate basic research findings for application 
in clinical practice. The methodological advances needed 
for this purpose, as mentioned by the experts, should be 
developed whilst taking into account the need for enhanced 
conceptualization and research operationalization. The 
mechanisms underlying etiology and treatment response in 
mental disorders should be the subject of research as well as 
the relationship between somatic and mental comorbidity, 
with the purpose of translating this knowledge into clinical 
intervention research for mental disorders. Clinical mental 
health research is relatively underfunded and should receive 
specific attention in Horizon 2020 funding programs.
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